| |
HCV patients (n = 365)
|
|---|
|
% (n) or mean ± SD
|
|---|
|
Age (years)
|
54.54 ± 12.7
|
|
Men /Women (n)
|
44.9% (164) / 55.1% (201)
|
|
Race (n)
| |
|
White
|
76.7% (280)
|
|
Multiracial (Brown)
|
13.8% (51)
|
|
Black
|
9.3% (34)
|
|
Type 2 diabetes (n)
|
23.1% (83/359)
|
|
Dyslipidemia (n)
|
20.1% (72/358)
|
|
High-blood pressure (n)
|
43.5% (156/359)
|
|
Obesity (BMI ≥ 30)
|
29.4% (106/360)
|
|
BMI
|
27.57 ± 5.02
|
|
Metabolic Syndrome (n)
|
23.2% (83/358)
|
|
Hypothyroidism (n)
|
17.3% (62/359)
|
|
Previous alcohol use (n)
|
8.4% (30/359)
|
|
Previous CVE (n)
|
5.0% (17/359)
|
|
HCV genotype (n)
| |
|
1
|
79.4% (289/364)
|
|
2
|
2.2% (8/364)
|
|
3
|
17.9% (65/364)
|
|
4
|
0.5% (2/364)
|
|
HOMA-IR
|
3.18 ± 4.24
|
|
AST (U/L)
|
63.36 ± 50.84
|
|
ALT (U/L)
|
68.84 ± 51.27
|
|
Alkaline phosphatase (U/L)
|
83 ± 34.62
|
|
GGT (U/L)
|
102.07 ± 110.32
|
|
Creatinine (mg/dL)
|
0.89 ± 0.6
|
|
Total cholesterol (mg/dL)
|
157.25 ± 36.06
|
|
HDL (mg/dL)
|
52.11 ± 16.31
|
|
LDL (mg/dL)
|
85.01 ± 31.22
|
|
Triglycerides (mg/dL)
|
101.81 ± 52.5
|
|
Liver histology
| |
|
Fibrosis (n = 364)
| |
|
F0
|
7.4% (27)
|
|
F1
|
28.0% (102)
|
|
F2
|
18.1% (66)
|
|
F3
|
15.9% (58)
|
|
F4
|
30.5% (111)
|
|
Inflammation (n = 300)
| |
|
A0
|
5.7% (17)
|
|
A1
|
40.3% (121)
|
|
A2
|
36.7% (110)
|
|
A3
|
17.3% (52)
|
|
Steatosis (n = 354)
| |
|
0
|
44.9% (159)
|
|
1
|
32.5% (115)
|
|
2
|
16.7% (59)
|
|
3
|
5.9% (21)
|
- ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; CVE: cardiovascular event; HDL: high-density lipoprotein; HOMA-IR: Homeostatic Model of Assessment; LDL: low-density lipoprotein; GGT: gamma glutamyl transferase; HCV: hepatitis C virus; SD: standard deviation
